Search alternatives:
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
sizes decrease » scores decreased (Expand Search), rivers decreased (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
sizes decrease » scores decreased (Expand Search), rivers decreased (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
-
1
-
2
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
4
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
5
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
6
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
7
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
8
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
9
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
10
-
11
-
12
-
13
Frequency distribution of SOLEC at baseline and follow-ups in WAD grade 2 and WAD grade 3.
Published 2024Subjects: -
14
-
15
-
16
Baseline descriptive characteristics of trial participants (n = 140) with and without dizziness.
Published 2024Subjects: -
17
Frequency distribution of SOLEC at baseline and follow-ups in the NSEIT and NSE groups.
Published 2024Subjects: -
18
-
19
Baseline descriptive characteristics of trial participants with dizziness, by treatment group.
Published 2024Subjects: -
20